Show simple item record

dc.contributor.authorSax, MJ
dc.contributor.authorGasch, C
dc.contributor.authorAthota, VR
dc.contributor.authorFreeman, R
dc.contributor.authorRasighaemi, P
dc.contributor.authorWestcott, DE
dc.contributor.authorDay, CJ
dc.contributor.authorNikolic, I
dc.contributor.authorElsworth, B
dc.contributor.authorWei, M
dc.contributor.authorRogers, K
dc.contributor.authorSwarbrick, A
dc.contributor.authorMittal, V
dc.contributor.authorPouliot, N
dc.contributor.authorMellick, AS
dc.date.accessioned2020-12-22T04:49:16Z
dc.date.available2020-12-22T04:49:16Z
dc.date.issued2016-12-20
dc.identifierpii: 13387
dc.identifier.citationSax, M. J., Gasch, C., Athota, V. R., Freeman, R., Rasighaemi, P., Westcott, D. E., Day, C. J., Nikolic, I., Elsworth, B., Wei, M., Rogers, K., Swarbrick, A., Mittal, V., Pouliot, N. & Mellick, A. S. (2016). Cancer cell CCL5 mediates bone marrow independent angiogenesis in breast cancer. ONCOTARGET, 7 (51), pp.85437-85449. https://doi.org/10.18632/oncotarget.13387.
dc.identifier.issn1949-2553
dc.identifier.urihttp://hdl.handle.net/11343/258148
dc.description.abstractIt has recently been suggested that the chemokine receptor (CCR5) is required for bone marrow (BM) derived endothelial progenitor cell (EPC) mediated angiogenesis. Here we show that suppression of either cancer cell produced CCL5, or host CCR5 leads to distinctive vascular and tumor growth defects in breast cancer. Surprisingly, CCR5 restoration in the BM alone was not sufficient to rescue the wild type phenotype, suggesting that impaired tumor growth associated with inhibiting CCL5/CCR5 is not due to defects in EPC biology. Instead, to promote angiogenesis cancer cell CCL5 may signal directly to endothelium in the tumor-stroma. In support of this hypothesis, we have also shown: (i) that endothelial cell CCR5 levels increases in response to tumor-conditioned media; (ii) that the amount of CCR5+ tumor vasculature correlates with invasive grade; and (iii) that inhibition of CCL5/CCR5 signaling impairs endothelial cell migration, associated with a decrease in activation of mTOR/AKT pathway members. Finally, we show that treatment with CCR5 antagonist results in less vasculature, impaired tumor growth, reduced metastases and improved survival. Taken as a whole, this work demonstrates that directly inhibiting CCR5 expressing vasculature constitutes a novel strategy for inhibiting angiogenesis and blocking metastatic progression in breast cancer.
dc.languageEnglish
dc.publisherIMPACT JOURNALS LLC
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleCancer cell CCL5 mediates bone marrow independent angiogenesis in breast cancer
dc.typeJournal Article
dc.identifier.doi10.18632/oncotarget.13387
melbourne.affiliation.departmentClinical Pathology
melbourne.affiliation.departmentMedical Biology (W.E.H.I.)
melbourne.source.titleOncotarget
melbourne.source.volume7
melbourne.source.issue51
melbourne.source.pages85437-85449
dc.rights.licenseCC BY
melbourne.elementsid1184286
melbourne.contributor.authorPouliot, Normand
melbourne.contributor.authorRogers, Kelly
dc.identifier.eissn1949-2553
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record